Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Drotrecogin alfa (activated) in Septic Shock
NCT00604214Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2008
- Primary completion
- Sep 2011
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 18
01
Overview
Phase 3, randomised, double-blind trial in septic shock comparing Drotrecogin alfa (activated) with Placebo (2 arms). Primary endpoint: 28-Day All-Cause Mortality. Started Mar 2008; status: completed.
02
Drugs
drotrecogin alfa
03
Conditions
septic shock
Beyond the preview
Go deeper on NCT00604214.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00604214.